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Prevalence of Poor Performance Status in Lung
Cancer Patients
Implications for Research
Rogerio C. Lilenbaum, MD,* John Cashy, PhD,† Thomas A. Hensing, MD,†‡ Susan Young, PhD,†‡
and David Cella, PhD†‡
Introduction: Performance status (PS) is a standard functional classi-
fication in oncology research and practice. However, despite its wide-
spread use, little is known about the prevalence of poor PS in lung
cancer patients, in relation to other cancers, based on the assessments of
health care providers and patients.
Methods: Data from two quality of life studies were pooled for
analysis. Analyses were performed on the subset of patients with
lung cancer (n  503) from the entire population of cancer patients
(n  2885). The prevalence of poor PS (defined as PS  2–4 on a
0–4 scale) was determined for lung cancer patients.
Results: Prevalence of poor PS among lung cancer patients was
34% when estimated by providers and 48% when estimated by
patients themselves. Agreement between providers and patients was
only fair (weighted [kappa]  0.41). For both advanced and early
stage disease, lung cancer patients were at the highest risk for poor
PS compared with other common cancers.
Conclusions: The prevalence of poor PS is quite high in lung cancer
patients. Providers tend to underestimate poor PS. Specific clinical
trials and treatment guidelines for this patient population are ur-
gently needed.
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Assessment of performance status (PS) in cancer patientsprovides prognostic information and guides treatment
intervention.1–6 PS scores are based on a patient’s ability to
perform daily activities and are designed to provide a mea-
sure of impairment as a function of tumor burden. Two main
PS scales are routinely used in oncology: Karnofsky (KPS)
and Eastern Cooperative Oncology Group (ECOG PS). The
KPS ranges from 0 to 100, in 10-point increments, to define
11 different PS levels from dead (0) to fully normal func-
tioning (100). ECOG PS has six levels ranging from 0 (fully
ambulatory without symptoms) to 5 (dead). Typically pa-
tients with an ECOG PS of 0 and 1 (or KPS 80, 90, and 100)
are labeled as having “good” PS for clinical research pur-
poses, whereas those patients with ECOG PS of 2, 3, and 4
are often ineligible for major clinical trials.
Several issues regarding PS in cancer patients need
further clarification. First, the prevalence of poor PS in lung
cancer patients remains unknown. Reporting of PS is not
routinely included in patient records or required by cancer
registries. Estimates from clinical trials consistently underes-
timate the prevalence of poor PS patients in clinical prac-
tice.7–10 Second, studies have shown discordance between the
PS assigned by oncologists compared with the PS provided
by the patients themselves.8,9,11,12 Assuming that patients are
better judges of their own health status, this discrepancy
further compounds the difficulties of using PS as a reliable
prognostic indicator or as a selection factor for participation
in clinical trials. Third, PS can be affected by cancer-related
symptoms or by preexisting comorbid conditions.13 Although
it may be helpful to divide patients into those whose PS is
compromised primarily by cancer from those whose PS is
compromised by concomitant illnesses, this is not routinely
performed in clinical practice or in research studies.
Based on this background, the current analysis was un-
dertaken to: (1) determine the prevalence of poor PS in patients
with lung cancer; and (2) evaluate the concordance between
provider-rated and patient-rated PS.
PATIENTS AND METHODS
Two large databases were pooled for these analyses.
Both studies were conducted after obtaining approval from
institutional review boards. Both studies included survey
results from outpatients and inpatients at the participating
institutions. The first database, “BIOQOL” (Bilingual Inter-
cultural Oncology Quality of Life) is from a study conducted
between 1994 and 1996. Participating institutions included:
Rush-Presbyterian Medical Center, Chicago, IL; Cook County
Hospital, Chicago, IL; San Juan Oncology, San Juan, PR; San
Juan VA, San Juan, PR; San Juan City Hospital, San Juan, PR;
Grady Memorial Minority Community Clinical Oncology Pro-
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gram, Atlanta, GA; and Emory University, Atlanta, GA. This
study evaluated the impact of language, culture, and literacy
upon QOL of patients with cancer and HIV disease.
The Q-score database contains data collected in 1995
and 1996 from Rush-Presbyterian Medical Center, Chicago,
IL; Northwestern University Medical School, Chicago, IL;
Johns Hopkins University Medical Center, Baltimore, MD;
Fox Chase Cancer Center, Philadelphia, PA; and the Medical
College of Ohio, Toledo, OH. These sites participated in a
project to evaluate the comparability of four widely used cancer
QOL questionnaires: The Cancer Rehabilitation and Evaluation
System,14 European Organization for Research and Treatment of
Cancer QOLQuestionnaire—Core 30,15 The Functional Assess-
ment of Cancer Therapy-General (FACT-G),16 and Medical
Outcomes Study Short Form 36.17
The combined sample size consisted of 3329 patients.
Patients with HIV disease (n  444) were excluded, leaving
a pooled cancer sample of 2885 patients. A separate set of
analyses was completed on the subset of patients with lung
cancer (n  503).
In both source studies, health care providers and patients
independently completed identical versions of the ECOG PS
scale (0 “normal activity,” 1 “some symptoms, but no bed
rest during daytime,” 2  “bed rest for less than 50% of
daytime,” 3  “bed rest for more than 50% of daytime,” 4 
“unable to get out of bed”). Concordance between providers and
patients was determined based on the respective responses to the
completed ECOG PS scale. Poor PS was defined as a rating of
2, 3, or 4.
RESULTS
Demographic data are summarized in Table 1. There
were a similar number of men and women in the cancer
cohort, and the majority of patients (83%) were treated as
outpatients. Just over half the patients were whites (57%),
with the remainder being either African American (22%) or
Hispanic (19%). Twenty-eight percent of patients had a
diagnosis of breast cancer, followed in order by cancer of the
colon, head and neck, lung, lymphatic system, and prostate.
Baseline demographics of lung cancer patients were similar
to the overall dataset, except for a slightly higher proportion
of men and older patients. Nearly 20% of lung cancer patients
were treated as inpatients and nearly half were receiving
chemotherapy when the assessment was taken.
Prevalence of Poor PS
Among all patients with cancer, the majority was clas-
sified as having a good PS (0 of 1), whether assessed by the
patient (61%) or the provider (78%). The second most prev-
alent group consisted of patients with PS2: 28% as assessed
by patients and 15% by the provider, with the remainder of
patients having PS3 and 4. In patients with lung cancer, a
similar pattern was observed, but the prevalence of poor
performance status was higher overall (Table 2). Nearly half
of the lung cancer patients (48%) rated their PS as poor
(versus 39% in the overall population). Based on providers,
one-third (34%) of lung cancer patients had poor PS versus
22% in the overall population. The prevalence of PS3 was
similar between patient and providers (10% and 14%, respec-
tively). The prevalence of PS 4 was low in all groups, with
the greater prevalence seen in lung cancer patients’ self-
assessments (3%).
We investigated the prevalence of poor PS in relation-
ship to age and gender and found no significant correlation
(data not shown). Data on other variables, such as stage and
specific tumor type, were not always available and could not
be correlated. Likewise, follow-up data on these patients was
not uniformly available and an association with tolerance to
treatment or overall survival could not be obtained.
Provider:Patient Concordance
Fewer than half of the PS ratings provided by patient
and providers agreed with one another: 47% of overall
sample and 43% of lung cancer sample. Adjusting for chance
agreement, and weighting close disagreement more than
distant disagreement, the weighted [kappa] coefficient ranged
from 0.39 to 0.41, considered to be in the “fair” range (Table
3). When patients and providers disagreed about performance
status, it was far more likely to be in the direction of provider
underestimation of impairment (39% underestimation versus
14% overestimation).
In an attempt to investigate factors that can lead to
discordance in PS assessments, we divided patients into three
groups based on agreement between patients and providers,
worse PS by patients, and worse PS by providers. All three
TABLE 1. Baseline Characteristics of All Patients and Lung
Cancer Patients in the Combined BIOQOL/Q
All Patients
(n  2885)
Lung Cancer Patients
(n  503)
Gender (%)
Male 46 58
Female 54 42
Age, yr (mean) 57.4 60.2
Diagnosis (%)
Breast cancer 27.9 ––
Colon cancer 15.2 ––
Head and neck cancer 14.2 ––
Lung cancer 17.4 100
Non-Hodgkin’s lymphoma 5.5 ––
Hodgkin’s disease 0.6 ––
Prostate cancer 7.1 ––
Other 10.6 ––
Unknown primary 1 ––
Race (%)
White, non-Hispanic 57 53
Black 22 26
Hispanic 19 21
Other 2 0.5
Inpatient (%) 17 20
Current treatments (%)
Radiation 18 23
Chemotherapy 41 46
Hormone therapy 12 3
BIOQOL, bilingual intercultural oncology quality of life.
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groups were similar with respect to age and gender. When
analyzed by FACT scores, as a surrogate for baseline disease
characteristics, we found no significant correlation with re-
spect to discordance.
Relative Risk of Poor PS
The relative risk of having poor PS by tumor type and
stage was also determined. Both provider and patient ratings
were evaluated. Because they had the lowest risk of poor PS,
patients with localized breast cancer were set as the reference
group for these analyses. Using this cohort as the benchmark,
the risk of having poor PS was calculated for other tumor
types using both patient and provider ratings of PS. We
required at least 100 per patient cohort to include it in the
analysis (this excluded 12 patients with localized lymphoma).
All studied groups had a higher risk of poor PS compared
with patients with localized breast cancer. That risk was
about five-fold in advanced lung cancer patients and al-
most three-fold in localized lung cancer using patient-rated
PS (Figure 1). When considering provider-rated PS, the
risk of poor PS in advanced lung cancer was almost 12
times that of localized breast cancer; whereas for localized
lung cancer it was about was about six times that of
localized breast cancer.
TABLE 2. Patient-Rated and Provider-Rated ECOG PS, Lung Cancer Patients (n  503)a
Patient-Reported
ECOG PS
Provider-Reported ECOG PS
0 1 2 3 4 Total
0 59 38 6 4 0 107 (22.0)
1 43 77 21 2 0 146 (30.0)
2 16 69 53 20 2 163 (33.5)
3 2 19 25 22 1 70 (14.4)
4 0 3 1 7 3 15 (3.1)
Total 121 207 106 55 6
(24.4) (41.8) (21.4) (11.1) (1.2)
All values inside parentheses indicate percentages.
a Eight patients were missing patient-rated PS, two patients were missing provider rated PS.
ECOG PS, Eastern Cooperative Oncology Group Performance Status.
TABLE 3. Provider:Patient Concordance on Performance
Status Ratinga
All Patients
(n  2837)
Lung Cancer Patients
(n  493)
Agreement 47% 43%
Provider underestimate 39% 38%
Provider overestimate 14% 19%
Test of symmetry S(10)  39.7b S(10)  53.3b
Kappa 0.26 0.24
Weighted kappa 0.41 0.39
a Because of missing data on 48 patients, total sample for these comparisons
was 2837.
b p  0.0001.
FIGURE 1. Comparison of relative risk of
poor performance status (patient rated) by
tumor type and stage.
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DISCUSSION
To our knowledge, this is the first attempt to prospec-
tively determine the prevalence of poor PS in lung cancer
patients in the United States. Because these patients are not
routinely enrolled in clinical trials, and information about PS
is missing from cancer evaluation forms, the magnitude of
this issue in the management of lung cancer patients has been
underestimated. We have found that poor PS is rather prev-
alent among patients with cancer. Nearly 2 of every 5 cancer
patients (39%) in this study of 2885 patients rated their PS as
poor (i.e., ECOG 2, 3, or 4). The risk of poor PS was greatest
for patients with advanced disease, particularly those with
advanced lung cancer. Half the patients with lung cancer,
regardless of stage, rated their PS as poor (49%), whereas
34% of their providers did the same. These estimates are
similar to other published data on the prevalence of poor PS
in lung cancer patients. In a longitudinal study of 536 lung
cancer patients, Buccheri and colleagues found that 50%
were rated ECOG PS 2, 3, or 4 by their providers at diagno-
sis.12 Radzikowska and colleagues evaluated PS in patients
with lung cancer using a large (n 20,561) population-based
registry in Poland.18 They found that approximately 30% of
patients had an ECOG PS rating of 2, and another 12% had
a rating of 3 or 4, making the prevalence of poor PS 42% in
their patient population.
Our data show that the concordance between patient PS
assessments and provider assessments is only fair. Using the
patient data, the incidence of poor PS across all tumor types
may be as high as 39%; however, using the provider data, the
rate is only 22%. Patient and provider ratings matched in less
than half the cases; when there was not agreement, it was
usually that patients reported their PS as poorer than did their
providers. For the subset of lung cancer patients, the rate of
over and underestimation by providers compared with pa-
tients was similarly high. We were not able to identify
specific factors that lead to under- or overestimation of the PS
based on our data. Several reasons have been proposed to
explain this discrepancy, including underreporting of symp-
toms by patients to enable more aggressive treatment; failure
on the part of the physician to be more specific about PS; or
dismissal of non–cancer-related causes of PS impairment.
Ando and colleagues compared interobserver agreement on
PS ratings as assessed by 206 patients with NSCLC, their
nurses, and their oncologists in a prospective study.11 On-
cologists assessed 71% of the patients as having a good PS,
but only 59% of patients assessed their PS as good (p 
0.007). Nurses were also more optimistic in their assessments
than were patients, and there were no significant differences
in the assessments between nurses and oncologists. On the
other hand, survival in this cohort was better correlated with
the oncologist-assessed PS rather than the patient’s self-
assessment. This observation suggests that oncologists may
take into consideration other factors besides the patient’s PS
on their assessment of overall prognosis. In addition, an
inherent selection bias may be present. Insofar as treatment
decisions are based on the oncologist-assessed PS, a patient
with a self-assessed PS2 may receive more aggressive treat-
ment if assessed as PS1 by the oncologist, which may, in turn,
lead to improved survival.
A study by Blagden and colleagues compared PS assess-
ments between oncologists and patients with cancer before
confirmation of the cancer diagnosis.9 Patients with a suspected
diagnosis of lung cancer (n 101) assessed their own PS at the
first clinic visit while waiting to be seen by the oncologist.
Oncologists performed a blinded assessment of PS, and a re-
search nurse collected the data and monitored outcomes. Al-
though agreement on PS was observed in only 50% of the cases,
both patient-assessed and oncologist-assessed PS correlated with
survival in Cox regression models.
Our data have limitations. Approximately 20% of lung
cancer patients were hospitalized and nearly 50% were un-
dergoing chemotherapy at the time their PS was assessed.
Although this most likely contributed to lower the PS of the
group as a whole, our figures are in conformity with the other
studies referenced above. Furthermore, this reflects a less
selected and arguably a more realistic pool of lung cancer
patients seen in clinical practice rather than outpatients who
are not receiving active treatment. Second, we do not have
survival data and therefore cannot correlate PS with outcome,
as other studies have done. An analysis of disease-related symp-
toms and PS, based on the same database, has been recently
published and showed a direct correlation between symptoms
and worsening PS.19 Last, we did not have access to comorbidity
data. Recent reports indicate that a high comorbidity index
may contribute to a poor PS and may have an independent
impact on overall outcome.20,21 This is the subject of
ongoing investigations.
In summary, a significant percentage of patients in oncol-
ogy practice presents with a poor PS. The risk of poor PS is
greatest for lung cancer patients, particularly those with ad-
vanced disease. Determining PS is subjective and varies be-
tween the patient and provider. The implications of these find-
ings for clinical research and clinical practice are manifold. First,
we propose that PS ratings be incorporated into the initial
patients’ assessments, and recorded in the patient’s standard
staging form, as currently mandated by tumor registries. Like
stage, PS is strongly correlated with prognosis, and access to this
information would be invaluable for clinical and research pur-
poses. Second, patients should also provide a measure of their
performance status. This would allow physicians and nurses to
gain more insight into their patients’ sense of well-being, which
may have implications for management. Third, a more standard-
ized PS scale, perhaps less variable and less subjective, and
above all more reproducible, would be an important contribu-
tion. Last, a substantial percentage of patients with lung cancer
are currently not being captured into research studies and dedi-
cated clinical trials in patients with poor PS are urgently needed.
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